News and Trends 13 Jul 2022 Sanofi sells two portfolios of established products to Neuraxpharma …in the CNS field in more than 50 countries. The first portfolio combines 15 products addressing CNS disorders and ranging across psychiatry and neurology. The second portfolio includes two products… July 13, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 10 Jul 2017 Meet the CEO of Minoryx, the Spanish Biotech Fighting Rare Disease …CNS at large enough amounts. That’s what MIN-102, as a best-in-class drug for a CNS disorder, can do. MIN-102 is also the metabolite of pioglitazone, a drug that has been… July 10, 2017 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Jan 2025 Ten first-in-class drugs on track for FDA approval in 2025 …Without sufficient I2S, GAGs accumulate in cells throughout the body, leading to progressive damage that affects multiple organs and the central nervous system (CNS). This accumulation results in a range… January 16, 2025 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Nov 2024 Six exosome therapy companies driving development in the field …is being evaluated in a preclinical program for graft-versus-host disease (GvHD). Aruna Bio AB126 aimed at treating CNS conditions AB126 demonstrated ability to cross the blood-brain barrier AB126 set to… November 12, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 21 Aug 2024 The promise of antisense oligonucleotides in precision medicine …and oncology. CNS disorders It could be argued that antisense oligonucleotides hold the most promise in CNS disorders, and there is currently a lot of research being done in this… August 21, 2024 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
2024 biotech funding tracker: recent highlights …1 in obesity OnCusp Therapeutics (United States): $100 million series A | oncology assets | preclinical in solid tumors Myrobalan Therapeutics (United States): $24 million series A | CNS disease… February 23, 2024 - 1 minutemin - By Aurore Michelin Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment …system (CNS) disorders while the Neuraxpharm Group is a pharmaceutical company focused on CNS therapies. Under the agreement, Minoryx grants Neuraxpharm exclusive European rights to its lead candidate leriglitazone, a… November 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 25 Jan 2024 Eight mental health biotech companies trying to make a difference to people’s lives …nervous system (CNS) conditions that currently have limited treatment options, company Axsome has already succeeded at being a major player in the mental health space, after its drug for major… January 25, 2024 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 30 Oct 2017 French Biotech Closes €19M IPO to Treat Narcolepsy and Alzheimer’s Theranexus debuts on Euronext Paris raising €19.6M that will support the development of its pipeline of CNS drugs for narcolepsy, Parkinson’s, Alzheimer’s and neuropathic pain. Theranexus, based in Lyon, starts… October 30, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 Drug for acute treatment of social anxiety disorder did not meet primary endpoint …drug, PH94B, was designed to treat people living with anxiety, depression and other central nervous system (CNS) disorders announced the topline results on Friday (July 22). Tolerability profile Previous results… July 25, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Virtual trials growth leads to Cambridge Cognition acquiring eClinicalHealth Cambridge Cognition is looking to accelerate its growth through the acquisition of eClinicalHealth Ltd (eCH). Cambridge Cognition is an active player in the central nervous system (CNS) market, supplying digital… October 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2017 Schizophrenia and Drug Delivery Biotechs Sign a Major Pharma Partner …Autifony’s CNS drugs, including its lead candidate, AUT00206. The biotech, which spun out from GSK to develop therapies for hearing loss, has decided to focus on CNS disorders, with two… December 19, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email